Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting

Rhea-AI Summary

Coeptis Therapeutics Holdings, a biopharmaceutical company, will present data on the development of SNAP-CAR NK cells at the ASGCT Annual Meeting. The Company aims to revolutionize cancer treatment with a universal targeted cell therapy that eliminates the need for HLA matching.

Positive

• Coeptis Therapeutics is developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases.

• The Company's abstract for the development of SNAP-CAR NK cells will be featured at the ASGCT Annual Meeting, showcasing their progress in the field.

• Coeptis is pioneering a first-in-class fully universal targeted cell therapy, combining scalable and cost-effective cell generation with SNAP-CAR technology.

• The integration of these platforms has the potential to revolutionize cancer treatment by offering antigen-agnostic targeted cell therapies, without the need for HLA matching.

Negative

• None.

WEXFORD, Pa., May 2, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to announce that the Company's abstract for development of SNAP-CAR NK cells will be featured as a poster presentation at the 2024 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, being held virtually and in-person in Baltimore, MD on May 7-11, 2024.

Dr. Carrie Stoltzman, Director of Cell Biology at Deverra Therapeutics will be presenting data on behalf of Coeptis regarding the development of the SNAP-CAR NK platform, designed to target multiple antigens and potentially address a wide range of cancers.

"The presentation at ASGCT marks a significant milestone in our endeavor to develop innovative cell therapy platforms for cancer and other diseases," stated Dave Mehalick, President and CEO of Coeptis Therapeutics. "Coeptis is poised to pioneer a first-in-class fully universal targeted cell therapy by combining a highly scalable and cost-effective cell generation platform with universal SNAP-CAR technology. The integration of these two platforms has the potential to revolutionize cancer treatment by offering fully universal, antigen-agnostic targeted cell therapies, without the need for HLA matching. We are excited to continue advancing these groundbreaking technologies toward first-in-human clinical trials."

Presentation Information

Session Title: Thursday Posters: Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies

Session Date/Time: 5/9/2024 12:00:00 PM
Presentation Room: Exhibit Hall
Final Abstract Number: 1325

About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer and infectious diseases. The Company is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com/.

Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the risk that the integration of the Deverra licensed assets will disrupt current plans and operations of the Company; (3) the inability to recognize the anticipated benefits of the newly-licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (4) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (5) costs related to integrating the newly-licensed Deverra assets and pursuing the contemplated asset development paths; (6) changes in applicable laws or regulations; (7) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (8) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.

Contacts
Coeptis Therapeutics, Inc.

IR@coeptistx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-announces-poster-data-presentation-at-american-society-of-gene--cell-therapy-asgct-27th-annual-meeting-302134117.html

SOURCE Coeptis Therapeutics

FAQ

What will Coeptis Therapeutics present at the ASGCT Annual Meeting?

Coeptis will present data on the development of SNAP-CAR NK cells at the ASGCT Annual Meeting.

Who will be presenting the data on behalf of Coeptis at the ASGCT Annual Meeting?

Dr. Carrie Stoltzman, Director of Cell Biology at Deverra Therapeutics, will be presenting data on behalf of Coeptis.

When and where will the ASGCT Annual Meeting take place?

The ASGCT Annual Meeting will be held virtually and in-person in Baltimore, MD on May 7-11, 2024.

What is the potential impact of Coeptis' technology on cancer treatment?

Coeptis aims to revolutionize cancer treatment by offering fully universal, antigen-agnostic targeted cell therapies that eliminate the need for HLA matching.